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Naturally, development of adaptive immunity following HRV infection affects the immune
response. However, it is currently unclear whether or not HRV re-exposure within a short
time frame leads to an altered innate immune response. The “experimental cold model” is
used to investigate the pathogenesis of HRV infection and allows us to investigate the
effects of repeated exposure on both local and systemic innate immunity.
Methods
40 healthy male and female (1:1) subjects were nasally inoculated with HRV-16 or placebo.
One week later, all subjects received HRV-16. Baseline seronegative subjects (n = 18) were
included for further analysis.
Results
Infection rate was 82%. Primary HRV infection induced a marked increase in viral load and
IP-10 levels in nasal wash, while a similar trend was observed for IL-6 and IL-10. Apart from
an increase in IP-10 plasma levels, HRV infection did not induce systemic immune effects
nor lower respiratory tract inflammation. With similar viral load present during the second
HRV challenge, IP-10 and IL-6 in nasal wash showed no increase, but gradually declined,
with a similar trend for IL-10.
Conclusion
Upon a second HRV challenge one week after the first, a less pronounced response for sev-
eral innate immune parameters is observed. This could be the result of immunological toler-
ance and possibly increases vulnerability towards secondary infections.
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Introduction
In the recent decade, it has become clear that bacterial sepsis may induce an immunosup-
pressed state called “sepsis-induced immunoparalysis”[1, 2], a form of immunological toler-
ance which renders the host unable to clear primary infections leading to increased
vulnerability towards secondary infections[3]. This immunologically tolerant state is charac-
terized by both innate as well as adaptive immunodysfunction, such as functional defects in
leukocytes, downregulation of cytokines and immunostimulatory membrane-bound recep-
tors, accompanied by the upregulation of negative costimulatory molecules[3, 4]. A similar
phenomenon is observed with virulent respiratory virus infections, such as influenza, which
predispose to secondary bacterial or fungal infections[5, 6].
Human rhinoviruses (HRVs) are the most frequent cause of the common cold[7, 8] with
prevalence estimates as high as 80% of the adult population[9]. HRV infection results in the
production of inflammatory cytokines and chemokines[10–14], and subsequent recruitment
of immune cells into the nasopharyngeal[15] and bronchial mucosa, and secretions[11–14]. In
addition, HRV-specific neutralizing antibodies are produced, resulting in seroconversion
approximately 28 days later[11, 16]. HRVs consist of three species, HRV-A, HRV-B and the
more recently discovered HRV-C[7]. Due to its high virulence, HRV-C can cause systemic
and severe respiratory infections in previously healthy subjects[7]. This has mainly been
reported for children, although several adult cases have also been described[7, 17]. Although
HRV-A and HRV-B may cause severe infections in young children, immunocompromised
patients, and/or patients with pre-existing respiratory diseases[18–21], it is unknown to what
extent these species induce systemic immunological effects or lower respiratory tract disease in
healthy adult subjects. Furthermore, although in vitro studies indicate that HRV can also
induce immunosuppressive or tolerance mechanisms[22, 23], this has never been investigated
in humans in vivo.
In the present study, we investigated the local respiratory tract and systemic immune
response following challenge with HRV-16 (a HRV-A species) using the so-called “experimen-
tal cold model”. This model is widely used to investigate the pathogenesis of HRV infection,
including the effects on pulmonary function[24], allergies[10], chronic obstructive pulmonary
disease (COPD)[25], and asthma exacerbations[24, 26]. Subjects were re-challenged with the
same virus one week after the first challenge, to investigate whether the primary HRV infection
modulates the innate immune response against the second HRV exposure. A one-week inter-
val was chosen, as at this time point the innate immune response induced by the first infection
is expected to be largely resolved and specific antibodies have not yet been produced to a large
extent[16, 27, 28]. We recently demonstrated that seropositivity for HRV is associated with a
virtually nullified immune response upon HRV challenge [29]. Therefore, we only analyzed
data from seronegative subjects in the current study.
Our data indicate that, despite similar viral loads upon both challenges, a second HRV chal-
lenge one week after the first results in less pronounced response of several innate immune
parameters. This could be the result of immunological tolerance and may be associated with
increased vulnerability towards secondary infections.
Materials and methods
Subjects
This randomized, placebo-controlled study was part of a larger trial also investigating effects of
serostatus and gender on the HRV-induced immune response[29]. This study is registered at
ClinicalTrials.gov (NCT01823640, participant recruitment and follow-up: March-May 2013).
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The authors confirm that all ongoing and related trials for this intervention are registered. As
this was a pilot study, no power calculation was performed. After approval by the local medical
ethics committee CMO Arnhem-Nijmegen (NL42503.091.12; CMO 2012/476), 40 healthy,
non-smoking, male and female subjects (ratio 1:1), aged 18–35 years gave written informed
consent to participate in the study. All study procedures were in accordance with the declara-
tion of Helsinki. Subjects were screened and excluded if they had a (febrile) illness within four
weeks before the HRV-challenge, a pre-existent lung disease, or a history of allergic rhinitis.
Subjects were not allowed to take (prescription) drugs throughout the study.
Study design
A flowchart of the study, based on infection rate (further detailed in ‘antibody titer analysis’
section) is depicted in Fig 1 and the study design is depicted in Fig 2. Stratification was based
on sex and serostatus as follows: Subjects with the same sex were grouped in two groups of 10
Fig 1. Flowchart of the study. S+ indicates seropositive at baseline; S- indicates seronegative at baseline.
https://doi.org/10.1371/journal.pone.0191937.g001
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subjects (2x n = 10 males; 2x n = 10 females; in total n = 40) subjects. Each group of 10 subjects
consisted of roughly 50% seronegatives and 50% seropositives, based on the baseline antibody
titers to HRV-16, measured at the screening visit (assay and cutoff value detailed in “antibody
titer analysis” section below). Subsequently, one group of the same sex (n = 10) was random-
ized to the placebo-HRV group, while the other (n = 10) was randomized to the HRV-HRV
group. Randomization was carried out by an independent nurse using the sealed envelope
method. Subjects were inoculated by an independent nurse with either HRV-16 by instillation
of 102 TCID50 (Tissue Culture Infectious Dose in 50% of subjects, based on previous studies
[30]) units of HRV-16, diluted in 0.5 mL 0.9% saline, (n = 20; 10 males; 10 females), or placebo
(0.9% saline; n = 20; 10 males; 10 females) into each nostril. Subjects remained in the recum-
bent position for two minutes after instillation and refrained from touching their nose for 30
minutes. Seven days later, all 40 subjects underwent challenge with HRV-16. For the analyses
described in this manuscript, only seronegative subjects were included, as serostatus was
shown to exert profound effects on the HRV-induced immune response, which was virtually
absent in seropositive subjects[29]. Furthermore, we did not stratify our analyses for gender, as
we found no differences in any parameters between males and females[29].
HRV-16 virus
Safety-tested Good Manufacturing Practice (GMP+) grade inoculum pools of HRV-16 were
supplied by Respivert Ltd. (MM#400472 Lot#R2011038, London, UK). Each cryovial con-
tained 0.2 mL of HRV-16 at a dose of 2102 TCID50 units/mL and was diluted in Hartmann’s
solution to a concentration of 102 TCID50 units/mL and stored at -80˚C. Per infection day,
one aliquot of HRV-16 was cultured in fourfold on a MRC-5 cell monolayer in 10-fold dilu-
tions of samples, positive and negative controls in order to assess infectivity. Cell plates were
placed at 33˚C with 5% CO2 for seven days and observed for the development of cytopathic
effects (CPE). The Reed-Muench formula was used to calculate the viral titer[31]. Viral titers
were all in the expected infectivity range (101−102 TCID50 units/mL) and positive and negative
control wells positive and negative for CPE, respectively.
Fig 2. Experimental design of the study.
https://doi.org/10.1371/journal.pone.0191937.g002
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Antibody titer analysis
A standard end-point neutralization assay for HRV-16 was used to quantify levels of HRV-
neutralizing antibodies in the serum of every subject at baseline (virus neutralization titer
[VNT] <1:4) and seropositive subjects (VNT1:4) to exclude subjects who were seropositive
to HRV-16 for the analyzes described in this manuscript, to assess seroconversion (fourfold
increase in antibody titer at day 28 post-challenge; day 28 in the HRV-HRV group and day 35
in the placebo-HRV group; Fig 1). The assay was performed on HEL cells at 37˚C and 5%
CO2. Two-step serum dilutions starting at 1:4 were incubated with 10
2 TCID50 HRV-16 for 1
h at 37˚C before inoculation on HEL cells. Serum controls were included on each plate to test
for toxicity, and a positive control of anti-HRV-16 antiserum was added to each test plate. The
formation of CPE was examined daily and after 7 days the cultures were scored for CPE. The
Reed-Muench formula was used to calculate the antibody titer[31]. Cells with>50% CPE/well
were scored antibody negative and50% CPE as antibody positive. HRV-infection was
defined as positive viral load and/or seroconversion (fourfold increase in antibody titer at
day 28 post-inoculation) compared with baseline[24].
Nasal wash
Nasal washings for viral load and cytokine quantification were collected daily from subjects
according to the method described by Naclerio[32]. Nasal wash from two nostrils was pooled,
centrifuged (6000 rpm, 4˚C, 20 minutes), and stored at -80˚C until analysis.
Viral load
Non-specific HRV viral load was determined from nasal wash as described previously[33] and
performed at the laboratory of medical microbiology at the Radboudumc according to QCMD
regulations. Briefly, nucleic acids were extracted from each sample using the MagNA Pure LC
(with Total Nucleic Acid Isolation Kit) and PCRs were performed on the LightCycler 480 with
Probes Master Mix (Roche Diagnostics, Almere, The Netherlands) using commercial validated
primer and probe-mixes (Diagenode, Liège, Belgium; Table B in S1 File). Cycling conditions
were 95˚C for five minutes, followed by 40 cycles of 95˚C (15 sec), 55˚C (15 sec) and 72˚C (20
sec). Virus amount was recorded semi-quantitatively based on the cycle threshold value (Ct
value). All samples in which virus was detected (Ct<40) were considered as having a positive
viral load. For samples in which no virus was detected, the Ct value was set as 40 to allow fold
change calculations. Fold change from baseline (Ct = 40) was calculated using the formula
2ΔCt.
Symptoms
We previously showed that the HRV-16 batch used in this study does not result in significant
induction of cold symptoms[29]. Therefore, we focused on lower respiratory tract and sys-
temic symptoms in the current study. To assess these, all subjects filled out an online symptom
diary (LimeSurvey Project Hamburg, Germany), using questions from the validated Wiscon-
sin Upper Respiratory Symptom Survey-24 (WURSS-24)[34], indicative for a lower respira-
tory tract/systemic respiratory infection (headache, sinusitis, cough, chest tightness, dyspnoea,
fever, shivering, body ache and malaise). Symptoms were assessed prior to viral/placebo chal-
lenge and then twice daily, to take into account circadian variations, until day 28. The severity
of each symptom was rated on a six-point scale.
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Peak Expiratory Flow
To evaluate whether HRV influenced pulmonary function (lower respiratory tract effects),
Peak Expiratory Flow (PEF) was measured during each visit using a peak flow meter (PFM20,
Omron Healthcare Europe B.V., Hoofddorp, The Netherlands). PEF was determined twice
during each visit and the highest value was used. An affected lower respiratory tract was
defined as a>20% decrease in PEF of the predicted values of their corresponding age, gender,
and stature[35].
Cytokine analysis
Nasal wash and ethylenediaminetetraacetic acid (EDTA) anticoagulated blood samples were
collected at various time points (Fig 1) centrifuged (6000 rpm, 4˚C, 20 minutes) and stored at
-80˚C until analysis. Concentrations of interferon (IFN)-γ, tumor necrosis factor (TNF)-α,
interleukin (IL)-1β, IL-6, IL-8, IL-10 were measured using a simultaneous Luminex assay
(Milliplex; Millipore, Billerica, MA, USA). Interferon gamma-induced protein (IP-10) was
measured using ELISA (R&D Systems, Minneapolis, MN, USA). Lower detection limits were
3.2 pg/mL for IFN-γ, TNF-α, IL-1β, IL-6, IL-8, IL-10, and 156 pg/mL for IP-10.
Statistical analysis
According to the Kolmogov-Smirnov test, all data were non-normally distributed. Therefore,
demographic data are presented as medians [interquartile range] and between-group compari-
sons were made using Mann-Whitney U tests. All other data are presented as geometric mean
and 95% CI. Because there was an interindividual variation in the peak of acute infection rang-
ing from day 1–4 after HRV inoculation, differences were analyzed on log-transformed peak
levels in the first four days post-challenge using paired and unpaired Student’s t-tests. Statisti-
cal analyses were performed using Graphpad Prism version 5.0 (Graphpad Software, San
Diego, CA, USA). Two-sided p-values <0.05 were considered statistically significant.
Results
Baseline subject characteristics
Baseline characteristics of the entire study population (n = 40, before exclusion of subject as
detailed below) are listed in Table A in S1 File). There were no significant differences in base-
line characteristics between the groups. No adverse events occurred during the trial.
Infection rate
A flowchart based on infection rate is depicted in Fig 1. Seven subjects displayed a positive
viral load in nasal wash before challenge with HRV, hence they were excluded from all subse-
quent analyses. In 27 of the remaining 33 subjects (82%), HRV challenge resulted in infection
(positive viral load and/or seroconversion; antibody titers of all subject provided in Table C in
S1 File). The six subjects who showed neither positive viral load at any of the time-points post-
challenge, nor seroconversion were categorized ‘not infected’ and were also excluded from all
subsequent analyses. Furthermore, as explained in the introduction and materials and meth-
ods section, 9 subjects who were HRV-seropositive at baseline were excluded from the subse-
quent analyses. Characteristics of the 18 remaining baseline HRV-seronegative infected
subjects who were included for the final analysis showed no significant differences between
groups (Table 1).
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Viral load
Viral load in nasal wash increased following HRV infection (Fig 3). At day 7, viral load was still
increased, and remained at a similar level upon a second challenge with the same virus (Fig 3).
Cytokines in nasal wash
HRV infection did not increase the production of IFN-γ, TNF-α, IL-1β and IL-8. However, a
transient increase in levels of IP-10 in nasal wash, and a similar trend for IL-6 and IL-10 was
observed (Fig 4). In subjects who were challenged with HRV twice, the first HRV inoculation
resulted in an identical immune response compared with subjects who received HRV once
(Fig 4).
However, following the second HRV challenge, levels of IP-10 and IL-6 in nasal wash
showed no further increase, but decreased significantly. A similar trend was observed for IL-
10 (Fig 4). IFN-γ, IL-1β, and TNF-α levels in nasal wash were below the detection limit in vir-
tually all subjects, and no clear profiles were observed following HRV infection.
Systemic and lower respiratory tract responses
Plasma levels of IFN-γ, TNF-α, IL-1β, IL-6, IL-8, and IL-10 were below the detection limit in
virtually all subjects at all time points. In the few subjects who displayed detectable levels of
Table 1. Demographic characteristics of the 18 seronegative subjects who displayed positive infection that were included in the final analysis. Parameters were
assessed during the screening visit. M: male, F: female. BMI: body mass index. Data are presented as medians [interquartile range].
placebo-HRV
n = 7
M (n = 3)
F (n = 4)
HRV- HRV
n = 11
M (n = 6)
F (n = 5)
total group
n = 18
p value between groups
Age (yrs) 22[21–26] 22[22–25] 22[21–25] 0.51
Height (cm) 175[166–182] 175[168–184] 175[168–183] 0.82
Weight (kg) 73[66–88] 71[64–78] 72[66–79] 0.56
BMI (kg/m2) 23[22–25] 23[21–24] 23[22–25] 0.41
https://doi.org/10.1371/journal.pone.0191937.t001
Fig 3. Viral load levels in nasal wash following placebo inoculation and HRV challenge (panel A) and following two HRV challenges separated by one week time (panel
B). Panel C shows the peak levels in the first four days post-challenge in the group that received placebo, followed by a HRV challenge (bars 1 and 2), and in the group
that were challenged with HRV twice (bars 3 and 4). Data are represented as geometric mean and 95% CI.
https://doi.org/10.1371/journal.pone.0191937.g003
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these cytokines, values were very low (approximately 10 pg/mL), in most cases already present
as baseline, and did not increase following HRV infection. IP-10 levels were detectable in
plasma already at baseline, but HRV infection after placebo inoculation did not result in signif-
icantly increased plasma levels (Fig 5). In subjects who were challenged with HRV twice, a
more pronounced increase was observed after the first inoculation, although this response was
not significantly different compared with that observed in subjects who received HRV once.
Fig 4. Cytokine levels in nasal wash following placebo inoculation and HRV challenge (panels A, D, and G) and following two HRV challenges separated by one week
time (panels B, E, and H). Panels C, F, and I show the peak levels in the first four days post-challenge in the group that received placebo, followed by a HRV challenge
(bar 1 and 2), and in the group that were challenged with HRV twice (bar 3 and 4). Data are represented as geometric mean and 95% CI. Lower detection limits were 3.2
pg/mL for IL-6 and IL-10, and 156 pg/mL for IP-10.
https://doi.org/10.1371/journal.pone.0191937.g004
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Upon the second HRV challenge however, a significant decrease was observed compared with
the first (Fig 5).
HRV infection resulted neither in systemic symptoms, nor in symptoms indicating a
descending respiratory tract infection (Figure A in S1 File). Furthermore, HRV infection did
not affect PEF, as all subjects produced values>80% of their individual predicted values at all
time-points, and PEF did not change after HRV challenge (Figure B in S1 File).
Discussion
In the present study, we show that the response of several innate immune parameters is less
pronounced upon a second HRV challenge seven days after the first challenge.
We chose to investigate the influence of two consecutive HRV challenges within a short
time frame. As a consequence, the observed attenuated response of several innate immune
parameters to the second HRV exposure may be the result of tolerance. These results indicate
that viruses causing relatively mild illness also induce attenuation of innate immune responses
and may lead to increased vulnerability towards secondary fungal / bacterial infections, or
reactivation of viruses that reside latent in the human host[4]. This could have consequences
for vulnerable patient groups, such as the elderly, and might influence vaccination strategies.
This finding is supported by in vitro studies that have shown that HRV can induce immuno-
suppressive mechanisms[22, 23]. The effects observed in the present study are reminiscent of
“endotoxin tolerance”, observed after challenging healthy volunteers with bacterial lipopoly-
saccharide[36, 37], and might resemble some aspects of the severely immunosuppressed state
observed in patients with sepsis[3] and influenza infections[5]. As such, it is tempting to specu-
late that previous infection with relatively mild viruses such as HRV renders patients increased
vulnerable towards secondary bacterial and/or viral infections. However, additional studies are
warranted to assess the clinical relevance of our observations. The tolerance effect observed
could be due to desensitization effects on local immune cells or a type-I interferon induced
CD8 T-cell mediated anti-viral state where no replication occurs[38]. For instance, it was
shown that HRV can survive in alveolar macrophages and impair the cytokine responses to a
second challenge with bacterial ligands[23]. Along these lines, for influenza and respiratory
syncytial virus (RSV), previous work has demonstrated a post-viral desensitization of alveolar
Fig 5. Plasma IP-10 levels following placebo inoculation and HRV challenge (panel A) and following two HRV challenges separated by one week time (panel B). Panel
C shows the peak levels in the first four days post-challenge in the group that received placebo, followed by a HRV challenge (bar 1 and 2) and in the group that were
challenged with HRV twice (bar 3 and 4). Data are represented as geometric mean and 95% CI. Lower detection limit was 156 pg/mL.
https://doi.org/10.1371/journal.pone.0191937.g005
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macrophages to Toll-like receptor (TLR) ligands, associated with reduced NF-kappaB activa-
tion and chemokine production[5].
In our study, we only included seronegative subjects, because previous work has demon-
strated that serostatus alters both HRV-induced symptom scores[16, 39] as well as the HRV-
induced immune response, which we showed to be virtually nullified in seropositive subjects
[29]. As such, next to the pathophysiological consequences, our results indicate that a cross-
over design is neither feasible using a short interval, due to a suppressed innate immune
response, nor using a longer interval, due to antibody formation that starts approximately one
week after HRV infection[16] and severely impacts the immune response[29].
The mucosal immune response observed in the present study, reflected by the increase in
cytokines in nasal wash, is in line with various previous in vitro and in vivo studies[11–13, 40].
In response to HRV infection, IP-10 was in contrast to other cytokines, produced in nasal
wash of all subjects following infection. As such, our results are in accordance with previous
studies that have demonstrated that IP-10 is a sensitive marker for HRV infection[12, 41, 42].
IP-10 plasma levels did not significantly increase upon a single HRV challenge although a
trend was apparent, especially following the first HRV inoculation in subjects who were chal-
lenged with HRV twice. In addition, more subjects that were challenged twice demonstrated
positive infection (11 in the HRV-HRV group vs. 7 in the placebo-HRV group; Fig 2). Appar-
ently in this short time frame, the host is not yet capable to induce an effective innate immune
response to eliminate HRV, supportive of the immunological tolerance theory. The mild
increase of IP-10 plasma levels is in line with studies in asthmatic and COPD patients[41, 42].
In the absence of alterations of all other systemic markers measured, this relatively minor
increase might suggest spillover from the nasopharynx to the circulation, although production
by cells outside the nasopharynx cannot be excluded.
Apart from the increase in IP-10, neither systemic symptoms or immune effects were found
after HRV infection, nor effects on the lower respiratory tract were observed. These findings
suggest that, unlike what has been described for vulnerable groups such as young children,
immunocompromised patients, and/or patients with pre-existing airway diseases[18–21],
HRV-16 does not exert these effects in healthy subjects.
This study has several limitations. First, we included a relatively low number of subjects,
which probably explains that several differences did not reach statistical significance.
Second, we only studied healthy subjects, therefore the observed effects could be different
in a diseased population, such as those suffering from sepsis, which might display dysregulated
cytokine responses[37].
Third, we did not store the nasal wash cellular fraction and therefore could not assess cellu-
lar markers such as induction of antiviral genes such as type I or III interferons, which play
important roles in respiratory viral infections[43].
Finally, we chose to perform the second HRV challenge one week after the first, as at this
time point the innate immune response induced by the first infection is expected to be largely
resolved, but apparently, viral load and levels of the cytokines in nasal wash had not returned
to baseline yet. However, one would expect a further increase in these parameters after a sec-
ond HRV challenge in case of a normal immune response, while a similar viral load and fur-
ther decrease in cytokines was apparent. In addition, although tolerance is a plausible
explanation for the attenuated immune response, one could speculate about the possibility
that, albeit in relatively little quantities, anti-HRV specific antibodies are already present at this
time, which could also lead to attenuation of the immune response upon the second HRV-16
challenge. However, studies that investigated kinetics of HRV-induced neutralizing antibodies
make this theory less likely[44, 45]. These studies demonstrate that HRV-neutralizing antibod-
ies in both nasal wash and serum are low seven days after HRV inoculation, and their titers
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begin to rise at approximately two weeks after inoculation[44], although it should be men-
tioned that the conventional detection tests used in these studies might be less sensitive in
detecting HRV-specific antibodies than the tests that are used nowadays. Nonetheless, our
data also show that viral load remained elevated until day 28, when the majority of subjects dis-
played seroconversion. Therefore, it appears not to be possible to find a suitable time-window
to investigate the effects of consecutive HRV challenges without taking into account the possi-
bly confounding effects of the development of an adaptive immune response, leading to the
production of anti-HRV specific antibodies. Using a different HRV strain for the second HRV
challenge would eliminate the possible influence of HRV-16-specific antibodies on the
immune response.
In conclusion, we report that a second HRV challenge one week after the first results in a
less pronounced response of several innate immune parameters. This could indicate that rela-
tively mild viruses can also induce immunosuppression, possibly leading to increased vulnera-
bility towards secondary infections.
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